Cuorips Inc.
Stock Price Chart
2026/10/02 11:38 UpdatedPrice Trend
2026/10/02 11:38 UpdatedPrice & Trading Details
2026/10/02 11:38 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/10/01Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥38M | ¥23M | ¥175M | ¥212M |
| Gross Profit | ¥21M | ¥10M | ¥168M | ¥130M |
| Operating Income | -¥450M | -¥588M | -¥590M | -¥1,081M |
| Pretax Income | -¥450M | -¥588M | -¥590M | -¥1,081M |
| Net Income | -¥452M | -¥632M | -¥644M | -¥1,023M |
| EPS | -¥59.94 | -¥85.86 | -¥80.52 | -¥124.54 |
| Operating Margin | -1,176.75% | -2,547.34% | -336.90% | -509.23% |
| Balance Sheet | ||||
| Total Assets | ¥3,587M | ¥6,185M | ¥5,742M | ¥5,123M |
| Total Equity | ¥3,454M | ¥5,982M | ¥5,527M | ¥4,750M |
| Total Liabilities | ¥134M | ¥202M | ¥215M | ¥373M |
| Cash | ¥2,942M | ¥5,561M | ¥4,595M | ¥3,653M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 96.27% | 96.73% | 96.26% | 92.72% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | -¥402M | -¥451M | -¥813M | -¥1,060M |
| Investing CF | -¥9M | -¥35M | -¥120M | -¥35M |
| Financing CF | ¥11M | ¥3,125M | ¥145M | ¥204M |
| Free CF | -¥412M | -¥487M | -¥902M | -¥1,110M |
| Efficiency | ||||
| ROE | -13.09% | -10.57% | -11.66% | -21.53% |
| ROA | -12.60% | -10.22% | -11.22% | -19.96% |
Latest IR Information
-
Notice of Completion of Payment for Issuance of New Shares by Third-Party Allotment
Payment procedures for the issuance of new shares by third-party allotment have been completed. The total number of issued shares will increase from the current 8,273,376 shares to 8,893,076 shares after the payment. The offering method was a third-party allotment...
Read more -
Supplementary Explanation Materials on the Issuance of New Shares through a Third-Party Allotment and the Issuance of the First Unsecured Ordinary Bond — Raising a total of 4.0 billion yen to accelerate R&D for the next-generation pipeline
Raised a total of 4.0 billion yen through a third-party allotment of 3.0 billion yen for new shares and 1.0 billion yen for unsecured bonds. The allottee is JICVGI Opportunity Fund No. 1. The funds will be allocated to research...
Read more -
Notice regarding the issuance of new shares through a third-party allotment
issuance of 619,700 new shares through a third-party allotment at 4,841 yen per share to raise approximately 3,000 million yen. The funds will be allocated to R&D for next-generation cardiac cell sheets, catheter therapies, internal regeneration factor inducers, and MSC...
Read more -
Notice on Inclusion of Rehart® in Public Medical Insurance
The new drug Rehart® has been included in public medical insurance (date: 2026-09-01), with a covered reimbursement price of 53,200,000 yen and an applicable category of C2 (new function / new technology). The impact on future performance has already been...
Read more -
Upward Revision of Full-Year Earnings Forecast | July 2026
Qualips has revised its full-year consolidated earnings forecast for the fiscal year ending March 2027 upward, projecting sales of 540 million yen and net profit of 570 million yen. The adjustments are due to the reimbursement price decision for Rehart...
Read more
Latest News (5 items)
Company Information
About
Cuorips Inc. engages in the research, development, manufacture, commercialization, and sale of human iPS cell-derived cardiomyocyte sheets in Japan. The company offers cellular and tissue-based, and cell processing products. It also provides contract development and manufacturing, and consulting services. The company was formerly known as Cuore Inc. and changed its name to Cuorips Inc. in June 2017. Cuorips Inc. was incorporated in 2017 and is headquartered in Osaka, Japan.
